Literature DB >> 18443636

Peripherally-acting opioids.

Howard S Smith1.   

Abstract

Opioids are broad-spectrum analgesics with potent pain-relieving qualities but also with potential adverse effects related to both short-term and long-term therapy. Researchers have attempted to alter existing opioid analgesics, utilize different routes/formulations, or combine opioid analgesics with other compounds in efforts to improve analgesia while minimizing adverse effects. Exogenous opioids, administered in efforts to achieve analgesia, work by mimicking the actions of endogenous opioids. Endogenous opioids and their receptors are located in the brain (supraspinal areas), spinal cord, and periphery. Although opioids and opioid receptors in the brain and spinal cord have received much attention over many years, peripheral endogenous opioid analgesic systems have only been extensively studied during the past decade. It has been known since 1990 that following injection into the rodent hindpaw, D-Ala(2),N-Me-Phe(4), Gly(5)-ol-enkephalin (DAMGO) [a muopioid receptor agonist] probably exerts its antinociceptive effects locally, since the doses administered are too low to have an effect in the central nervous system (CNS). This notion has been supported by the observation that the quaternary compound morphine methyliodide, which does not as readily cross the bloodbrain barrier and enter the CNS, produced antinociception following intradermal administration into the hindpaw, but not when the same dose was administered systemically (subcutaneously at a distant site). With a growing appreciation of peripheral endogenous opioids, peripheral endogenous opioid receptors, and peripheral endogenous opioid analgesic systems, investigators began growing hopeful that it may be possible to achieve adequate analgesics while avoiding unwanted central untoward adverse effects (e.g. respiratory depression, somnolence, addiction). Peripherally-acting opioids, which capitalize on peripheral endogenous opioid analgesic systems, may be one potential future strategy which may be utilized in efforts to achieve potent analgesia with minimal side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443636

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  13 in total

Review 1.  Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Authors:  Wendy M Walwyn; Karen A Miotto; Christopher J Evans
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

2.  Modulating pain in the periphery: gene-based therapies to enhance peripheral opioid analgesia: Bonica lecture, ASRA 2010.

Authors:  Srinivasa N Raja
Journal:  Reg Anesth Pain Med       Date:  2012 Mar-Apr       Impact factor: 6.288

3.  Effects of intramuscular morphine in men and women with temporomandibular disorder with myofascial pain.

Authors:  Soo-Kyung Kang; Yeon-Hee Lee; Hyeji Park; Jin Y Ro; Q-Schick Auh
Journal:  Oral Dis       Date:  2018-07-06       Impact factor: 3.511

4.  Age Differences in the Time Course and Magnitude of Changes in Circulating Neuropeptides After Pain Evocation in Humans.

Authors:  Joseph L Riley; Yenisel Cruz-Almeida; Margarete C Dasilva Ribeiro; Corey B Simon; Nathan R Eckert; Maria Aguirre; Heather L Sorenson; Patrick J Tighe; Robert R Edwards; Shannon M Wallet
Journal:  J Pain       Date:  2017-04-29       Impact factor: 5.820

5.  Synovial fluid β-endorphin level in avascular necrosis, rheumatoid arthritis, and osteoarthritis of the femoral head and knee. A controlled pilot study.

Authors:  Kálmán Toth; István Barna; György Nagy; Karoly Wellinger; Gyöngyi Horvath; Tamas Bender
Journal:  Clin Rheumatol       Date:  2010-09-21       Impact factor: 2.980

6.  Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Authors:  Mariana Spetea; Petra Windisch; Yan Guo; Indre Bileviciute-Ljungar; Johannes Schütz; Muhammad Faheem Asim; Ilona P Berzetei-Gurske; Pal Riba; Kornel Kiraly; Susanna Fürst; Mahmoud Al-Khrasani; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2011-01-14       Impact factor: 7.446

Review 7.  Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?

Authors:  Hwoe Gyeong Ok; Su Young Kim; Su Jung Lee; Tae Kyun Kim; Billy K Huh; Kyung Hoon Kim
Journal:  Korean J Pain       Date:  2018-04-02

Review 8.  Mesotherapy: From Historical Notes to Scientific Evidence and Future Prospects.

Authors:  Massimo Mammucari; Enrica Maggiori; Domenico Russo; Chiara Giorgio; Gianpaolo Ronconi; Paola E Ferrara; Flora Canzona; Luciano Antonaci; Bartolomeo Violo; Renato Vellucci; Domenico Rocco Mediati; Alberto Migliore; Umberto Massafra; Barbara Bifarini; Fabio Gori; Massimo di Carlo; Stefano Brauneis; Teresa Paolucci; Piergiovanni Rocchi; Anna Cuguttu; Raffaele Di Marzo; Alessandro Bomprezzi; Stefania Santini; Manuela Giardini; Anna Rosa Catizzone; Fiammetta Troili; Dario Dorato; Alessandra Gallo; Costanza Guglielmo; Silvia Natoli
Journal:  ScientificWorldJournal       Date:  2020-05-01

Review 9.  Inhibitory Gi/O-coupled receptors in somatosensory neurons: Potential therapeutic targets for novel analgesics.

Authors:  Yevgen Yudin; Tibor Rohacs
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.370

Review 10.  Analgesic Potential of Essential Oils.

Authors:  José Ferreira Sarmento-Neto; Lázaro Gomes do Nascimento; Cícero Francisco Bezerra Felipe; Damião Pergentino de Sousa
Journal:  Molecules       Date:  2015-12-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.